SCHEMBL1180809

SCHEMBL1180809

COc1ccc(-c2cc(-c3cccc(OC)c3)on2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.78
RAB9A P51151 5/20 0.78
PTPN1 P18031 3/20 0.60
CYP3A4 P08684 2/20 0.60
CYP2C9 P11712 2/20 0.60
CYP2C19 P33261 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
ALDH1A1 P00352 3/20 0.59
HPGD P15428 2/20 0.59
MAPT P10636 2/20 0.57
KDM4E B2RXH2 1/20 0.57
MAPK1 P28482 1/20 0.57
PTGS2 P35354 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 1/20 0.55
TSHR P16473 1/20 0.55
HSD17B10 Q99714 1/20 0.55
HSD17B1 P14061 1/20 0.54
HSD17B2 P37059 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1180333 0.94 NPC1 (0.78) NPC1RAB9APTPN1CYP3A4CYP2C9
SCHEMBL31341199 0.90 NPC1 (0.63) NPC1RAB9APTPN1CYP3A4CYP2C9
SCHEMBL17084387 0.88 NPC1 (1.00) NPC1RAB9APTPN1CYP3A4CYP2C9
SCHEMBL17084385 0.88 NPC1 (1.00) NPC1RAB9APTPN1CYP3A4CYP2C9
SCHEMBL1181029 0.87 NPC1 (0.87) NPC1RAB9APTPN1CYP3A4CYP2C9
SCHEMBL17084393 0.87 NPC1 (0.72) NPC1RAB9APTPN1CYP3A4CYP2C9
SCHEMBL28664036 0.86 NPC1 (0.75) NPC1RAB9APTPN1CYP3A4CYP2C9
SCHEMBL30423076 0.86 NPC1 (0.75) NPC1RAB9APTPN1CYP3A4CYP2C9
SCHEMBL12171605 0.83 NPC1 (0.69) NPC1RAB9APTPN1ALDH1A1HPGD
SCHEMBL31341173 0.82 MAPT (0.65) NPC1RAB9ACYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046147-A1 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES UNIVERSITAT DES SAARLANDES (DE) 2011-02-24 US disclosed
US-20110046147-A1 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES UNIVERSITAT DES SAARLANDES (DE) 2011-02-24 US disclosed
US-20110046147-A1 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES UNIVERSITAT DES SAARLANDES (DE) 2011-02-24 US disclosed
EP-2190421-A2 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES Universität des Saarlandes (DE) 2010-06-02 EP disclosed
WO-2009027346-A2 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES Universität des Saarlandes (DE) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046147-A1 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES HSD17B1, HSD17B11, HSD17B2 NPC1 1544/4885RAB9A 3724/4885PTPN1 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.